Piper Jaffray Starts Theravance Biopharma (TBPH) at Overweight
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Piper Jaffray initiated coverage on Theravance Biopharma (NASDAQ: TBPH) with an Overweight rating and a price target of $42.
Shares of Theravance Biopharma closed at $25.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Theravance Biopharma (TBPH) Granted FDA Fast Track Status of Velusetrag for Idiopathic and Diabetic Gastroparesis
- BTIG Starts Mitek Systems (MITK) at Buy
- Goldman Sachs Starts Performance Food Group (PFGC) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!